The class of sodium-glucose cotransporter 2 (SGLT2) inhibitors is an integral part of the management of type 2 diabetes. Recent published clinical evidence has provided further guidance on the role of SGLT2 inhibitors in type 2 diabetes, as well as other indications such as heart failure and chronic kidney disease. This Environmental Scan will assess the current reimbursement of the SGLT2 drug class relevant to public drug programs.
CADTH is pleased to announce the launch of its new Post-Market Drug Evaluation Program.
This important initiative fills a key gap in Canada’s drug safety and effectiveness landscape and is an exciting example of how CADTH is delivering on the “Innovate” pillar from its 2022-2025 Strategic Plan.
CADTH recently experienced problems with its website hosting platform that prevented users from downloading documents from cadth.ca – including draft reimbursement recommendations and stakeholder feedback forms.
The issue has been resolved and all documents on our website are now accessible to everyone.
When the problem was identified, CADTH contacted sponsors and patient groups and provided them with copies of the draft recommendations and feedback forms for the reimbursement reviews currently open for feedback. Sponsors also received the reconsideration forms.